Can Indian CRAMS firms cash in on the global slowdown?
This article was originally published in Scrip
Will the global economic slowdown brighten short-term outsourcing prospects or would it cast a pall over India's custom research and manufacturing services (CRAMS) segment that is projected to touch $7.6 billion by 2012? While the jury is still out on the segment's prospects amid the turmoil, experts say that Indian CRAMS firms may have to offer more than mere cost arbitrage to rake in the moolah.
You may also be interested in...
Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.